Objective To evaluate whether cranberries are able to prevent postoperative urinary bacteriuria in patients undergoing pelvic surgery and receiving transurethral catheterisation.
Introduction
Urinary tract infections (UTIs) are a major health issue affecting 11% of all women each year with an economic burden of 2-3 billion dollars per annum for the US healthcare system. [1] [2] [3] The main risk factors are genetic factors, ageing, menopause, urogenital dysfunction, pregnancy and pelvic surgery. 4, 5 UTIs in urogynaecological patients occur especially after sling procedures and selfcatheterisations. 6 Up to 90% of gynaecologic surgery patients have indwelling catheters postoperatively and up to 20% have postoperative UTIs with Escherichia coli being the predominant pathogen isolated during these infections. 7, 8 During the last decade, uropathogenic E. coli (UPEC) have developed new mechanisms of antibiotic resistance, especially to b-lactams, sulfonamides and fluoroquinolones, which are commonly used against these infections.
9 Multidrug-resistant strains have spread globally in the hospital as well as community settings, increasing Clinical trial registration: ClinicalTrials.gov, www.clinicaltrials.gov, NCT01114347.
the difficulties of prevention and treatment. Nowadays it is essential to delay the onset and/or extension of bacterial resistance and preserve the activity of antibiotics as long as possible. 10 As previously shown, postoperative antibiotic prophylaxis during catheterisation did not reduce the rate of UTIs; 7 hence, alternative treatments need to be evaluated. The Vaccinium macrocarpon, also known as the American cranberry, has been investigated for its biological properties, along with its components Vaccinium macrocarpon and proanthocyanidins (PAC), which are responsible for the anti-adhesion activity against UPEC strains on the urothelial cells by inhibiting the synthesis of P-fimbriae and deforming the cell body of the bacterium. 11, 12 It has been demonstrated that the anti-adhesion effect was dose-dependent, requiring a daily intake of at least 36 mg PAC. 13 The active ingredient of the cranberry was shown significantly to reduce the incidence of UTIs in children and in older people at high risk for UTIs, for example due to long-term catheterisation or recurrent UTIs. 14, 15 As hospitalised women receiving postoperative catheterisation are at a higher risk for UTI, we conducted an intention-to-treat randomised controlled trial (RCT) to determine whether cranberry capsules compared with placebo lower postoperative bacteriuria in a high-risk population of women undergoing gynaecological pelvic surgery.
Methods
This is a single-centre, randomised, double-blind, placebocontrolled trial of patients who received postoperative transurethral catheterisation after pelvic surgery. The study was carried out in a French tertiary referral centre between 2010 and 2014.
Patients aged over 18 years, undergoing pelvic surgery with postoperative placement of an indwelling catheter for a minimum of 24 hours and with a sterile urine culture on the day of inclusion were considered eligible. Exclusion criteria were: known positive urine culture at baseline, preexisting self-catheterisation, treatment with anticoagulants and/or antibiotics for any other medical condition, history of urolithiasis, pregnancy, and breastfeeding. Once included, patients underwent urinary analysis on the day before the surgery. Whenever a culture came back positive, the study treatment was stopped and patient was excluded from the analysis.
Procedure
The day before surgery, patients underwent urinary analysis. The urine was collected by the patient in a sterile storage tube by discarding the first stream and collecting the middle stream after a careful vulvar toilet and holding the labia apart.
Perioperatively, participants received routine intravenous antibiotic prophylaxis with cefazolin, or clindamycin in case of allergy, within 1 hour from incision according to our hospital protocol. At the beginning of the intervention a Foley catheter was placed under sterile conditions.
On the day of surgery, participants were randomly allocated to either capsules of 36 mg cranberry (PAC) or placebo in a 1:1 ratio. Each patient was asked to selfadminister a pill containing a capsule (PAC or placebo) daily taken from day 0 (day of surgery and urinary indwelling) until day 10 every morning with a full glass of water.
During the period of hospitalisation, patients were interviewed and examined twice daily by the surgeon investigator for assessment of the general condition and clinical signs. The occurrence of any side effects was noted. Between discharge from the hospital and the planned visits on day 15 and day 40, the patients were asked to notify the investigator of the appearance promptly of any side effects. Also, patients were discharged with a prescription for urine analysis; this prescription allowed results of the urinalysis performed outside of the hospital scheduled visits to be gathered when patients saw their general practitioner (GP). At day 15 and day 40 after surgery, urine samples were collected and processed following the same protocol as above. If referring to a GP, urine samples were collected at the GP's office, where the patients were properly instructed by the GP or the nurse.
Outcomes
The primary outcome was the presence of postoperative culture-proven bacteriuria within the first 15 days after surgery and was defined as a urine culture growth >10 3 CFU/ ml (colony forming units per ml) of a single organism following national recommendations. Secondary outcome was bacteriuria within 40 days after surgery. Complementary outcome was the rates of E. coli infections by day 15 and day 40. Women who had a positive urine culture within the first 15 days were not included in the analysis for the secondary outcome (bacteriuria on day 40).
Statistics
All statistical analyses were performed using SAS© (SAS Institute, Cary, NC, USA) version 9.3. Continuous variables were expressed as mean and standard deviation or median with 25th and 75th percentiles and compared using the Mann-Whitney U test. Qualitative variables were expressed as proportions and compared using chi-square test (or Fisher exact test when appropriate). All P-values were twotailed and a P-value <0.05 was considered significant. All tests were performed before the unmasking of the two treatment groups. The sample size calculation was based on our hospital database revealing a postoperative UTI rate of 35% in 2008. To bring out a reduction of 50% 16 (from 35% to 17%) for bacteriuria with 80% power and an a error of 0.05, we estimated that 123 patients in each group were necessary. The statistical concept used was ITT (intention-to-treat) analysis. Considering a 10% loss of follow up, 136 women were deemed necessary in each arm. Nonstratified randomisation was performed using computergenerated random-size blocks (SAS software) by the methodologist of the Biostatistics Department of Nimes University Hospital appointed to the study. Randomisation was independent of recruiting investigators, study personnel and patients, who were masked to treatment assignment. The random allocation sequence was centralised to an online application.
Results
Patient flow is shown in Figure 1 . From September 2010 to February 2014, 272 women were included and randomised into the study. After randomisation, four patients were excluded from the PAC and 13 from the placebo group, leaving 132 and 123 patients in PAC and placebo groups, respectively ( Figure 1 ). No obvious differences in demographic parameters including age, BMI, smokers, intraoperative complications, length of hospital stay or length of catheterisation were observed between the two groups ( Table 1) . None of the patients required intermittent selfcatheterisation postoperatively. A total of 255 women received the treatment or placebo according to their randomisation. For 6 women of the PAC group and 7 women of the placebo group, urinary analysis results at day 15 were missing. 18 patients in the PAC group and 20 patients in the placebo group were lost to follow up, thus 108 women in the PAC group and 96 women in the placebo group were analysable. At day 40, 50 results were missing in the PAC group and 49 in the placebo group, leaving 82 and 74 for analysis, respectively (Figure 1 ).
For the primary outcome, 27% of PAC group patients (29/108; 95% CI 19-36%) and 25% of the placebo group (24/96; 95% CI 17-35%) developed bacteriuria within 15 days after surgery [relative risk (RR) 1.05; 95% CI 0.78-1.4] without significant difference for the two groups (P = 0.763). Specifically, 20 (19%) patients were positive for E. coli in the PAC group and 16 (17%) in the placebo group (RR 1.07; 95% CI 0.77-1.48]) without a significant difference.
On day 40 there was no significant difference for bacteriuria between the PAC [5/82 (6%); 95% CI 2-14%)] and placebo groups [3/74 (4%); 95% CI 0.8-11%)].
A similar result was obtained for E. coli infection with 1% (95% CI 0.03-6%) and 3% (95% CI 0.3-9%) for PAC and placebo, respectively. Escherichia coli was the most common bacterial source found. At day 15, E. coli was indeed detected in 11.9% of the bacterial cultures. Details of the different bacteria are presented in Table 2 .
Higher risk factors to develop postoperative bacteriuria were observed in older women and women with prolonged catheterisation (Table 3) . However, there was no significant difference in the incidence of bacteriuria between PAC and placebo groups for the different surgical procedures analysed (vaginal route surgery P = 0.142, vaginal mesh placement P = 0.3815, hysterectomies P = 0.773, and suburethral slings P = 0.940). Similarly, no significant differences were observed for clinical risk factors such as smokers or older women with a transvaginal mesh (smoker P = 1.00, catheterisation for more than 24 hours P = 0.732, women aged above 55 years with a vaginal mesh P = 0.188). A statistical subgroup analysis of obese women [body mass index (BMI) > 30] or women with catheterisation duration ≥3 days could not be performed due to low subject numbers. Regarding patients' symptoms, at day 2 one patient in the PAC group and two patients placebo group were symptomatic. At day 15, one patient in the placebo group was symptomatic. At day 40, six patients were symptomatic, all of them in the placebo group. All patients except for one at day 2 in the PAC group had negative urinalysis results.
Discussion

Main findings
This study demonstrates that cranberry capsules (PAC) do not reduce the risk of bacteriuria after pelvic surgery within 15 and 40 days of the surgery. Escherichia coli was the most common bacterial source, detected in 11.9% of the bacterial cultures at day 15. There was no statistical difference between PAC and placebo groups. Risk factors to develop postoperative bacteriuria were older age and prolonged catheterisation.
Strengths and limitations
Several strengths of our study may be highlighted: the prospective randomised placebo-controlled design and high standard of conduct from inclusion to randomisation, patients undergoing different type of surgical gynaecological procedure were included, follow-up patients, data collection, data management and statistical analysis. Statistical analysis was performed before unmasking the two treatment groups. Also, the information bias was reduced to a minimum by providing the women with a prescription of urine analysis at the time of discharge; in this way, even if performed at the GP's office, results were made available to the hospital's Microbiology Department. This helped to reduce the number of missing urinalysis results.
This study has also some limitations. This is a singlecentre study and therefore the study setting is limited to the University Hospital. Patients referred to the University Hospital, a tertiary care facility, may not be representative for the female population, as more complicated cases are treated in this setting. The number of subjects analysed was not enough to reach statistical analysis power. The number of patients lost to follow up was significantly higher than expected and bacteriuria incidence was lower than anticipated.
Interpretation (in light of other evidence)
The effect of cranberry on UTI has already been partially investigated. Previous studies that found a positive effect of cranberry had different study designs, which might explain the differences in the results observed. As an example, in a study by Afshar et al.
14 a protective effect in children was found, cranberry capsules significantly reducing UTI. However, the population analysed was smaller and clearly very different in terms of age and other baseline characteristics. Caljouw et al. 15 found a positive effect of the cranberry in older patients who were catheterised for more than 2 days, but they they did not observe the same effect in patients with shorter catheterisation times. Compared with that study, our patients were relatively younger (median age was 58 years for the PAC group and 59 years for the placebo group) and catheterisation times were shorter. Our results are in line with a recent Cochrane review that did not find any significant decrease of recurrent UTIs with cranberries as compared with placebo or other forms of treatment. 17 Also, the preventive effectiveness of cranberry was not significantly different from that of antibiotics. In addition, the efficacy of cranberry was analysed in patients undergoing radiotherapy for cervix or bladder cancer and, similar to our findings, no positive effect could be found. 18 Recently, Foxman et al. 19 published the results of a randomised controlled trial that, similar to our study, aimed to assess the efficacy of cranberry capsules in preventing UTI after surgery. Although target population and design were very similar, a striking difference in the results can be observed. They found that the use of cranberry extract tablets reduced the rate of UTI by half during the postoperative period. The discrepancy may be attributed first of all to the difference in the primary endpoint definitions and assessment. Secondly, in Foxman et al., 19 50% of patients were self-catheterised and treatment was administered postoperatively, as compared with our patients, who were not self-catheterised and for whom treatments were administered perioperatively. Similar to our study, no significant differences were found in a study by Juthani-Mehta et al. 20 in the prevention of bacteriuria or pyuria among older women in nursing homes with PAC versus placebo over 1 year.
Primary and secondary endpoints were defined as culture-proven bacteriuria within 15 and 40 days, respectively. Also, as with previous studies, we based the assessment on bacterial cultures and not on clinical signs. [20] [21] [22] [23] All women included in this study underwent pelvic surgery and symptoms such as frequency or dysuria are therefore not reliable signs postoperatively. Indeed, gynaecological patients are likely to suffer from urinary tract symptoms postoperatively due to the manipulation of the lower urinary tract. Very few women complained of symptoms and, importantly, except for one patient in the PAC group, none of the symptomatic women had positive urinalysis results. This observation is in agreement with the assumption that bacteriuria is a reliable outcome for UTI assessment.
Our study population was composed of patients undergoing pelvic surgery with different approaches, including the vaginal and abdominal approach, and therefore there was a different risk profile. Pelvic surgery, especially the vaginal approaches, involves manipulation of the external urethral meatus; however, the rate of bacteriuria was not increased in this specific high-risk population (P = 0.188). The only significant risk factor for postoperative bacteriuria was the length of catheterisation, with longer catheterisation leading to a higher rate of bacteriuria.
Conclusion
Postoperative UTIs are a burden on patients and the healthcare system, necessitating further research for effective prevention. With the rise of antibiotic-resistant strains, the use of antibiotics should be limited strictly to treatment therapies. Alternative methods are therefore being sought to prevent UTIs. Our findings show that cranberry capsules do not reduce the risk of bacteriuria after pelvic surgery. Further studies are needed to determine whether alternative therapies could lower the rate of bacteriuria in older women after pelvic surgery, to avoid medical practitioners prescribing unnecessary treatments for postoperative patients.
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